{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:59:14Z","timestamp":1785473954319,"version":"3.56.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the association of adjuvant intravesical Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy after transurethral resection of bladder tumor (TURBT) with bladder mucosal apoptosis index, recurrence-related outcomes, progression-free survival, and 12-month quality of life in patients with non-muscle-invasive bladder cancer (NMIBC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on 114 NMIBC patients who underwent TURBT at our hospital from January 2022 to December 2024, including 57 patients receiving postoperative intravesical BCG immunotherapy (BCG group) and 57 patients receiving TURBT alone without postoperative adjuvant intravesical therapy (control group). Tumor recurrence rates, progression-free survival (PFS), bladder mucosal apoptosis index, and quality of life (QOL-BREF) scores were compared between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline characteristics of both groups were balanced via propensity score matching (PSM) (P&amp;gt;0.05). The BCG group exhibited a significantly higher bladder mucosal apoptosis index (32. 13\u00a0\u00b1\u00a05.61) compared to the control group (18.72\u00a0\u00b1\u00a04.29) (P&amp;lt;0.001). Six-month and one-year recurrence rates were markedly lower in the BCG group (2 cases, 3.51%; 8 cases, 14.04%) versus the control group (9 cases, 15.79%; 21 cases, 36.84%) (P&amp;lt;0.001), with median PFS extended to 25 months (control group: 13 months, P&amp;lt;0.001). Pearson correlation analysis showed a positive correlation between apoptosis index and PFS (r=0.61, P&amp;lt;0.001), and multivariable Cox regression further indicated that a higher apoptosis index was independently associated with a lower risk of recurrence or progression. Preoperative QOL-BREF scores showed no significant difference between groups (54. 11\u00a0\u00b1\u00a05.96 vs. 54.03\u00a0\u00b1\u00a06.27, P&amp;gt;0.05), while postoperative scores were significantly higher in the BCG group (71.95\u00a0\u00b1\u00a08.23 vs. 63.47\u00a0\u00b1\u00a08.22) (P&amp;lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this retrospective propensity-score-matched cohort, adjuvant intravesical BCG immunotherapy after TURBT was associated with a higher bladder mucosal apoptosis index, lower recurrence risk, longer progression-free survival, and better 12-month QOL-BREF scores. These findings support the clinical relevance of apoptosis index and QOL assessment in postoperative NMIBC management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1856699","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:24:09Z","timestamp":1785471849000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Bladder mucosal apoptosis index and quality of life after adjuvant intravesical BCG therapy for non-muscle-invasive bladder cancer: a retrospective propensity-score-matched study"],"prefix":"10.3389","volume":"16","author":[{"given":"Hui","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Urology, Affiliated Nantong Hospital 3 of Nantong University, Nantong Third People\u2019s Hospital","place":["Nantong, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShuBin","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Nantong Hospital 3 of Nantong University, Nantong Third People\u2019s Hospital","place":["Nantong, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XianGen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Nantong Hospital 3 of Nantong University, Nantong Third People\u2019s Hospital","place":["Nantong, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fjurol.2024.102742","article-title":"French AFU Cancer Committee Guidelines - Update 2024-2026: Non-muscle invasive bladder cancer (NMIBC)","volume":"34","author":"Roumigui\u00e9","year":"2024","journal-title":"Fr J Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment ofbladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"Bmj"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn4118","article-title":"Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Gu\u00e9rin","volume":"15","author":"de Jong","year":"2023","journal-title":"Sci Transl Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612596","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: current treatment landscape and novel emerging molecular targets","volume":"24","author":"Claps","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31020079","article-title":"BCG and alternative therapies to BCG therapy for non-muscle-invasive bladder cancer","volume":"31","author":"Lidagoster","year":"2024","journal-title":"Curr Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.eururo.2025.02.010","article-title":"A systematic review of novel intravesical approaches for the treatment of patients with non-muscle-invasive bladder cancer","volume":"88","author":"Ghodoussipour","year":"2025","journal-title":"Eur Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2022.05.005","article-title":"Intermediate-risk non-muscle-invasive bladder cancer: updated consensus definition and management recommendations from the international bladder cancer group","volume":"5","author":"Tan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2363744","article-title":"N-803 plus BCG treatmentfor BCG-na\u00efve or -unresponsive non-muscle invasive bladder cancer: A plain language review","volume":"20","author":"Chamie","year":"2024","journal-title":"Future Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000003846","article-title":"Diagnosis and treatment ofNon-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.963877","article-title":"Immune status for monitoring and treatment ofbladder cancer","volume":"13","author":"Pan","year":"2022","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1159\/000538373","article-title":"The Eficacy and Safety ofHyperthermia Intravesical Chemotherapy in the Treatment ofNon-Muscle-Invasive Bladder Cancer: A Meta-Analysis","volume":"108","author":"Duan","year":"2024","journal-title":"Urol Int"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6707","article-title":"Optimal interval timing between transurethral resection of bladder tumors and Bacillus Calmette-Guerin perfusion","volume":"12","author":"Cai","year":"2023","journal-title":"Cancer Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00345-025-05473-z","article-title":"Utility ofMRI in NMIBC and feasibility of avoiding Re-TURB in carefully selectedpatients: a systematic review","volume":"43","author":"Saouli","year":"2025","journal-title":"World J Urol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2217\/fon-2023-0271","article-title":"CREST: phase III study ofsasanlimab and Bacillus Calmette-Gu\u00e9rin for patients with Bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk non-muscle-invasive bladder cancer","volume":"20","author":"Steinberg","year":"2024","journal-title":"Future Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2023.06.018","article-title":"Sequential intravesical gemcitabine\/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy","volume":"41","author":"Yim","year":"2023","journal-title":"Urol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03025-3","article-title":"Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial","volume":"30","author":"Li","year":"2024","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.08.001","article-title":"Bladder-sparing therapy for bacillus calmette-gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer: international bladder cancer group recommendations for optimal sequencing and patient selection","volume":"86","author":"Li","year":"2024","journal-title":"Eur Urol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-025-01645-7","article-title":"Advancements in the diagnosis, treatment, and risk stratification of non-muscle invasive bladder cancer","volume":"27","author":"Smani","year":"2025","journal-title":"Curr Oncol Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.12.005","article-title":"Oncologic outcomes ofSequential intravesical gemcitabine and docetaxel compared with bacillus calmette-gu\u00e9rin in patients with bacillus calmette-gu\u00e9rin-unresponsive non-muscle invasive bladder cancer","volume":"8","author":"Taylor","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03729-5","article-title":"Comparative study on the eficacy of low-dose and full-dose BCG bladder perfusion therapy","volume":"27","author":"Chen","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3892\/ol.2024.14400","article-title":"Perfusion drugs for non_muscle invasive bladder cancer (Review)","volume":"27","author":"Qian","year":"2024","journal-title":"Oncol Lett"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020245","article-title":"Carcinoma in situ (CIS): is there a difference in efficacy between various BCG strains? A comprehensive review of the literature","volume":"16","author":"Llano","year":"2024","journal-title":"Cancers"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11912-022-01350-9","article-title":"Novel therapies for high-risk non-muscle invasive bladder cancer","volume":"25","author":"Al Hussein Al Awamlh","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35966","article-title":"The current and future role of systemic therapy in non-muscle-invasive bladder cancer","volume":"131","author":"Lazarovich","year":"2025","journal-title":"Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)01897-5","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","volume":"406","author":"De Santis","year":"2025","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4111\/icu.20230042","article-title":"Treatment strategies for the Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder cancer","volume":"64","author":"Jeong","year":"2023","journal-title":"Investig Clin Urol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2458211","article-title":"Identification of multicohort-based predictive signature for NMIBC recurrence reveals SDCBP as a novel oncogene in bladder cancer","volume":"57","author":"Zhang","year":"2025","journal-title":"Ann Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-A summary of the 2024 guidelines update","volume":"86","author":"Babjuk","year":"2024","journal-title":"Eur Urol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.05.012","article-title":"Novel delivery systems and pharmacotherapeutic approaches for the treatment of non-muscle-invasive bladder cancer","volume":"7","author":"Guerrero-Ramos","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/mou.0000000000001330","article-title":"Antibody-drug conjugates for non-muscle invasive bladder cancer: current status and future development","volume":"35","author":"Wong","year":"2025","journal-title":"Curr Opin Urol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1856699\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:24:10Z","timestamp":1785471850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1856699\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":31,"alternative-id":["10.3389\/fonc.2026.1856699"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1856699","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"1856699"}}